Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
look like something come in UP , we HALTED !!!
Ok , but STOP CRY !!!
MORE INFORMATION ABOUT COMPANY
MORE INFORMATION ABOUT COMPANY
SergicalT. If revenue will be 5.1 Mil. is it make you more happy ?
SAN DIEGO--(BUSINESS WIRE)--
Innovus Pharmaceuticals, Inc. (“Innovus Pharma”) (INNV), today announced full year 2016 net revenues of $4.8 million compared to $0.7 million in revenues for the same period in 2015 and fourth quarter of 2016 net revenues of $1.7 million compared to $0.2 million in revenues for the same period in 2015.
“We believe our revenue growth for all of 2016 highlights the strength of our Beyond Human® Sales and Marketing platform that we acquired in March 2016 along with the high value products we are commercializing,” stated Bassam Damaj, President and Chief Executive Officer of Innovus Pharma. “Looking forward to 2017, we continue to be focused on increasing annual revenues to $15 million by executing on our goals of expanding our product lines and making our products commercially available in the United States and outside of the United States through our partners, and achieving profitability.”
Financial highlights for the year ended December 31, 2016 included:
• Net revenues totaled $4.8 million for the year ended December 31, 2016, compared to net revenues of $0.7 million for the year ended December 31, 2015.
• Gross margins increased to 77.5% for the year ended December 31, 2016, compared to 53.4% for the year ended December 31, 2015.
• Total operating expenses increased to $10.7 million and included $2.7 million in non-cash share-based compensation for the year ended December 31, 2016.
• Net loss totaled $13.7 million, or $0.15 per common share, for the year ended December 31, 2016. The net loss included interest expense of $6.7 million, of which $6.4 million was non-cash and related to amortization of debt discounts and the excess initial fair value of the embedded conversion features from our 2016 financing. The net loss also included a non-cash expense of $1.3 million for the net change in fair value of contingent consideration. Net loss for the year ended December 31, 2015 totaled $4.2 million or $0.08 per common share.
Financial highlights for the three months ended December 31, 2016 included:
• Net revenues totaled $1.7 million for the three months ended December 31, 2016, compared to net revenues of $0.2 million for the three months ended December 31, 2015.
• Gross margins increased to 78.2% for the three months ended December 31, 2016, significantly higher than gross margins for the three months ended December 31, 2015 which totaled 44.3%.
• Total operating expenses increased to $3.6 million and included $0.8 million in non-cash share-based compensation for the three months ended December 31, 2016.
• Net loss totaled $3.4 million, or $0.03 per common share, for the three months ended December 31, 2016. The net loss included a non-cash expense of $1.5 million for the net change in fair value of contingent consideration. The net loss also included interest expense of $0.7 million, of which $0.6 million was non-cash and related to amortization of debt discounts and the excess initial fair value of the embedded conversion feature from our 2016 financing. Net loss for the three months ended December 31, 2015 totaled $1.0 million or $0.02 per common share.
• Cash balance totaled $0.8 million at December 31, 2016.
Fourth quarter 2016 and recent developments:
• Notification was received to commercialize Zestra® in all 28 member countries of the European Union.
• Zestra® was approved for sale in South Korea through its partner J&H Co. LTD.
• Mr. Randy Berholtz was appointed as Executive Vice President, Corporate Development and General Counsel.
• Lertal® tablets, a clinically proven supplement for the relief of allergic rhinitis symptoms from NTC was in-licensed for the United States and Canada. Product will be launched under the brand name AllerVarx™.
• UriVarx™, clinically proven to reduce urinary urgency, accidents and both day and night frequency in Overactive Bladder (OAB) and Urinary Incontinence (UI), was launched under the Beyond Human® Sales and Marketing Platform.
• Entered into a $2.0 million per year exclusive license and distribution agreement with J&H Co. LTD granting them exclusive rights to market and sell Zestra® in South Korea.
• Zestra® multi-dose form for female sexual arousal, was launched under the Beyond Human® Sales and Marketing Platform in the U.S.
• Entered into an exclusive license and distribution agreement with Elis Pharmaceuticals granting Elis exclusive license to market and sell Zestra® in Lebanon.
• Initiated a pre-clinical and clinical program intended to evaluate the safety and efficacy of the combination of its supplement Vesele® for promoting sexual health with sildenafil indicated for treating erectile dysfunction.
The Company will host a conference call at 4:30 p.m. ET/1:30 p.m. PT today to discuss the financial results and recent business developments. To participate in the call, please dial 1-877-883-0383 for domestic callers or 1-412-902-6506 for international callers. Participant Elite Entry Number: 5095822. A replay of the call will be available for 30 days. To access the replay, dial 1-877-344-7529 domestically or 1-412-317-0088 internationally and reference Conference ID: 10102614. The replay will be available shortly after the end of the conference call.
Lets see last 30 min. will see who is who !!!
Loser voice....................
Same people like you told me you loser , back to July 2012 about NOK (was $1.64c. have 25K shares ) , and after September 3 2013 I'm laughing when NOK open morning $6.50c. and short was BURNED !!! Sold for $7.36c.after few months
BRAVO !!!! I'm in with 85K shares .. average 0.25c. and I have GERN 20K shares !!!
Opinion - YB ..The price to sales ratio for INNV is 5.13 ttm...this is about average for a going concern...but when you look at the P/S for 2017 it drops to 1!!! Anything below 2 is excellent, a P/S of 1 or lower is considered extremely undervalued. Think about it INNV's market cap is equal to its 2017 SALES sans Fluticare!!! This is why I'm not worried...***of course they do need to make 15 million in 2017***...I will be concerned if Dr. D revises sales downward...but if he reiterates 2017 revenues or god forbid for the shorts he INCREASES it!!!..!!!...holy shit we will be in for the ride of our lives!...
DAMAJ... doing Right - clean up house from all negativity ,,smart ,, investors .
News from TRUMP !!! “I’ll oppose anything that makes it harder for smaller, younger companies to take the risk of bringing their product to a vibrantly competitive market,” Trump told them. “That includes price-fixing by the biggest dog in the market, Medicare, which is what’s happening. But we can increase competition and bidding wars.”
Keep Dreaming.........................
,, DOG BARKING , BUT CARAVAN GOES ,, ......................
Adrock !? .....
can't understand why some people are already frustrated with Innovus on just the third day of trading for the new year.
Nothing has changed from last week, or two weeks ago or for that matter, two months ago. The company is still waiting for the FDA approval for its ANDA which we all know can take up to 36 months. Granted we are impatient but no bad news has been released. There is no dilution of shares. Innovus has not increased the shares outstanding since the approval and intends to do so only with specific purposes which will accelerate growth. The vote merely gave the CEO the flexibility to do so if an appropriate opportunity arises. Also (and I posted this before) the CEO purchased his $2.5 million worth of shares (6.25 million shares) at a 0.40 cent cost basis and I am positive is very cognizant of appropriate uses for any additional shares. I know that people on this board have expressed concerns about dilution but let's not create panic. Granted dilution without increasing shareholder value is always a negative. But if dilution increases future earnings and revenue at a rate faster than increased share count, then that is positive or accretive. Almost all mid-sized and large companies have utilized accretive dilution as an appropriate way to deliver increased shareholder value and have done so at many points in their history. So why all the fuss? Nothing has changed.
I have realistic expectations of Innovus as the new year starts. I am not going to panic when this stock moves down or up by 2 or 3 or 5 cents. The malicious market-makers are trying to short INNV but are not having much luck.
None of the nine (9) institutional investors is trying to sell and they have over 12 million shares.
These nine investors gave INNV $3 million in exchange for 12 million shares (priced at 0.25) and almost all that debt has now been converted before the maturity date so there is no issue there. While I am not able to speculate on what these investors will do in the future, I can hypothesize that they want INNV to go as high as it has the potential to go.
By the way, I am not making this stuff up. Please feel free to review a previous S1 (filed with the SEC 8/9/16), Pg-3.
Team my plan is to listen to the Q4 2016 earnings call (in mid-Feb), patiently wait for the FDA approval, get positive guidance for 2017 and gradually see the SP go up later this year. I own a lot of shares (more than I should own) but I truly believe in this company and its mid to long-term success possibilities. This company will not evaporate as some may have suggested. I am not going to get frustrated every day when this stock bounces-around because the fundamentals for INNV are in good shape despite the MM trying their best to manipulate/derail it. Hang-in there longs; our day is coming.
See Less
https://finance.yahoo.com/news/dr-bassam-damaj-innovus-pharma-133000736.html
SAN DIEGO CA--(Marketwired - Oct 11, 2016) - Innovus Pharma ( OTCQB : INNV ) is one of those very rare microcap companies with real products, real revenues, and a proven record of rapid growth, according to a new updated analysis by CEOCFO magazine.
CEOCFO states that the San Diego-based consumer and pharmaceutical company pulled in more than $1 million product sales in the second quarter of 2016, an increase of over 400% compared to the first quarter of 2016. It's on track for more than $5 million in revenues for all of 2016 -- and $15 million in 2017, which would put Innovus Pharmaceuticals, Inc. ( OTCQB : INNV ) firmly in the black. Most important, the Company has acquired the worldwide rights to FlutiCare™, a nasal spray for allergy symptoms that Innovus will market over-the-counter (OTC).
"We believe there is incredible potential here," the Biotech Stock Review writes. Once FlutiCare™ "can be bought without a prescription, the overall market could expand to 77 million units (per year) or over $1 billion in sales."
"People have been surprised at the significant revenue growth," says CEO Dr. Bassam Damaj. "And with key mainstream drugs like FlutiCare™, the real growth is just starting," Damaj adds. "Our goal is to up-list to the NASDAQ exchange at the right time and grow to be a significant revenue-generating Company with earnings."
The secret of Innovus' success is conceptually simple: Acquire products that bring real benefits to patients and that already have strong revenues or have revenue potential, and sell them under the proprietary Beyond Human sales and marketing platform.
But that's easier said than done. It takes an experienced biotech and pharma chief executive like the Lebanese-born Damaj, 47, who trained at and has helped bring drugs to market at such major companies as Pfizer, Genentech, Pharmacopeia, Tanabe Seiyaku (now Mitsubishi-Tanabe) and Apricus Biosciences. "This is what I do best," he explains. "I'm very well known in the field, so I know what's out there, what will succeed in the marketplace, and what will make a difference in the lives of people."
It also helped that Damaj brought $2.5 million of his own money to the Company when he joined the Company in 2013, and has been able to raise $5 million more this year on the strength of his reputation for spotting the growth potential in products when others don't.
The money has enabled Innovus to acquire several moneymaking products in a broad range of areas, such as sexual health, vitality, vision, urology, and allergy relief. All are backed up by patent protection or proprietary formulations, and supported by clinical data; more are on the way.
One of the most successful purchases for Innovus was acquiring supplement company Beyond Human and its powerful marketing and sales platform. Beyond Human's lead product, BTH® Testosterone Booster, is a dietary supplement containing vitamins, zinc, and extracts of the herbs fenugreek and Eurycoma longifolia, which have been linked to increased testosterone levels and enhanced sexual function. That product had sales of $2.2 million in 2015 and is bringing significant revenues for Innovus, says Damaj.
Another top seller is Vesele®, a supplement that enhances blood flow and promotes both sexual health, as shown in a clinical use survey trial, Damaj says. Innovus acquired the product for $40,000 in 2015 and now it is the best-selling product for Company.
Strong clinical trials and patents also support Zestra®, a blend of oils that boosts female arousal, which Innovus acquired from Semprae Laboratories, Inc. In addition, Innovus's product lineup includes EjectDelay® for premature ejaculation, Androferti® (in the US and Canada) for overall male reproductive health and sperm quality, and BTH Vision Formula.
But both Damaj and investors are particularly excited by Innovus's 2015 merger with Novalere FP, which brought to Innovus the worldwide rights to the FlutiCare™ brand.
Fluticare™ (containing the active pharmaceutical product fluticasone propionate nasal spray) is a type of corticosteroid used to fight symptoms of allergies, such as stuffy and runny noses, itching, and sneezing -- and is a key product in the $1 billion annual market for nasal steroids. FlutiCare™ now is a prescription generic version of the top-selling brand-name drug Flonase, but is expected to go OTC by the end of 2016. "FlutiCare™ will put us on the map as an important mainstream pharmaceutical company," says Damaj.
Read More
ITNS - is BIG PROBLEM with Outstanding
Out standing shares 1.50B Float 1.02B
voice of LIFE TIME LOSER ..... stockzoom come in up from his dark hole ,only if stock negative territory ...
stockzoom - you very small Liar. Friday was stop -loss sale Vol. was 13Mil. yesterday Vol. was over 5Mil with UP .... and 4Mil was bought between 0.31-0.36c. WHAT ARE TALKING ABOUT 20 MIL. NICE TRY , BUT EVERYONE KNOWS YOUR HISTORY ...
don't touch him ...STOCKZOOM is DARK HOLE , LIFE BURNING NEGATIVE ...
CNN Cover NEWS INNV Target $1.34c. The 1 analysts offering 12-month price forecasts for Innovus Pharmaceuticals Inc have a median target of 1.34, with a high estimate of 1.34 and a low estimate of 1.34. The median estimate represents a +354.24% increase from the last price of 0.30.http://money.cnn.com/quote/forecast/forecast.html?symb=INNV
SCARY MOVIE ,,,.... GUYS NOBODY LISTEN TO YOU . LONGS , SHORTS , DAYTRADERS ALREADY DONE DD... QUESTION??? FOR YOU, WHY YOU SPEND YOUR TIME, WEEKEND TIME , FAMILY TIME... HERE ? WHY ? ... THATS RIGHT , MAKE IT SCARY MOVIE WITH YOUR PREDICTION ... GET YOUR COINS.... FEEL SORRY ABOUT YOU....BUT YOU VERY WEAK, VERY WEAK.. THANKS FOR SHARES 0.21c. p.s. play since 0.07c. .... was sold 0.50c. double free 25K.shares.. position.
You can check anytime ..... link FDA
http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Reports.ReportsMenu
23K .... Just CLEARED....
More COVER NEWS today ... Innovus Pharmaceuticals, Inc. (INNV), is an emerging leader in OTC and consumer products for men's and women's health and vitality. INNV has an upcoming FDA decision regarding the approval of the Fluticasone Propionate ANDA for FlutiCare™, which it has rights to market as an over-the-counter product worldwide. As a leading prescription brand with 40 million units sold in 2014, FlutiCare™ is capable of generating in excess of $100 million per year in revenue once full market penetration is achieved. FlutiCare™ would be competing with GlaxoSmithKline plc's (NYSE: GSK) Flonase®, which generated nearly $100 million in its first 16 weeks on the shelf, according to IRI figures. INNV recently announced record revenue of $1 million during the second quarter, driven by its recent acquisition of Beyond Human and organic growth across its core product lines. For the full year, management expects to reach the 'higher end' of its $3-5 million in projected revenue without factoring in any potential gains from FlutiCare™ -- a nasal allergy spray that's currently under review by the FDA. As a result, SeeThruEquity issued an update on August 15, 2016 on INNV and raised its target price to $1.00 per share.
http://www.baystreet.ca/viewarticle.aspx?id=443931
YES, Its good mistake or prediction , NEVER saw Zacks cover OTC pink stock ... something COOKING . !!!! Innovus Pharmaceuticals Inc (NASDAQ:INNV) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Wednesday. The brokerage presently has a $0.50 target price on the stock. Zacks Investment Research’s target price suggests a potential upside of 27.88% from the company’s current price
Never saw ZACKS INVESTMENT to cover OTC - pink Market penny stock .... but Surprise ...
Zacks Investment Research Upgrades Innovus Pharmaceuticals Inc (INNV) to Buy
August 17th, 2016
Innovus Pharmaceuticals logoInnovus Pharmaceuticals Inc (NASDAQ:INNV) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Wednesday. The brokerage presently has a $0.50 target price on the stock. Zacks Investment Research’s target price suggests a potential upside of 27.88% from the company’s current price.
According to Zacks, “Innovus Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company. It delivers non-prescription medicine and consumer care products to improve men’s and women’s health and vitality. It has a robust portfolio of sexual dysfunction treatments, cough, cold, respiratory disease treatments and pain management medication, as well as skin care products. Its male and female sexual health and vitality products include Zestra (R) to increase desire, arousal, and satisfaction in women; EjectDelay (R) for treating premature ejaculation; Sensum+ (TM) that increases penile sensitivity; Zestra Glide (R); and Vesele (R) to maximize nitric oxide beneficial effects on sexual functions and brain health. Innovus Pharmaceuticals, Inc. is based in San Diego, California. “
Innovus Pharmaceuticals (NASDAQ:INNV) traded down 5.115% on Wednesday, hitting $0.371. The company had a trading volume of 1,042,997 shares. The stock’s 50-day moving average price is $0.38 and its 200 day moving average price is $0.18. The company’s market capitalization is $32.34 million. Innovus Pharmaceuticals has a one year low of $0.03 and a one year high of $0.66.
I got Vesele........ its working Very Well........... p.s. But waiting almost two weeks... OUT OF STOCK
Today MA50 - 0.33c. by Friday can be MA50- 0.35c. next week 0.38c. WOW !!! ......... and ?
1-3c. its not Declay.... Yes, its can be for few minutes... pressure down to 0.34c-0.36c. but not 0.25 look Volume , its DRY...
sorry ... GOOD LUCK..
Sorry about I call you bro.. and sorry about my ENGLISH .I'm Ukrainian , but not try to be smart like you..... YOUR OPINION IS WEAK NOW ABOUT PRICE , and you know this ...anyway good like with your 0.30+ ..............
RFB.... Its to late , I was agree with you last week ... but now NO... If they want put down , they can do easy last week ... they cover already before... so now your opinion very weak... sorry bro ... & look chart ... 16 years trading... bro.
Yes, that's right... look AROON - indicator already 48.... its mean price going down few more days . put order 0.27c. & 0.32c.... CHART SAID & S-1 form SAID..
Look AROON on chart green line already 50 . its mean down pressure ,next week we will see 0.30c. , can be touch 0.25c. but very short time, few minutes, best put order 0.27c. S-1 form SAID THIS................................
Yes !!! But S - 1 SAID ... offering shares on a .25 warrant... , no VOL. NOW BIG BOYS WANA MORE CHEAP SHARES BEFORE FDA say OK !!!
I liked company , got 0.12. but S-1 CLEARLY SAID 0.25 -040 c.... sooner or later, ..... just wait... few todays...
KEEP DREAMING................. ITS FREE COUNTRY...
negativity bring in your Life even MUCH MORE NEGATIVITY...... keep doing bro.....................